This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
You play a critical role in the ABECMA treatment process, helping RRMM patients navigate their journey with ABECMA. Get information and tools you need to help support your patients below.
From the treatment process to adverse event monitoring and management information, it’s here—so you can continue to guide your patients throughout their treatment journey.
RRMM=relapsed/refractory multiple myeloma.
While regular check-ins with their healthcare team are still required, the following are NOT required for your patients with RRMM while they are responding to ABECMA:
Defined as being in market since 2021 as the first CAR T cell therapy in RRMM.
Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring. A single dose of ABECMA contains a cell suspension of 300 to 460 x 106 CAR-positive T cells in one or more infusion bags.
The ABECMA treatment journey requires close collaboration between a patient's primary oncologist and a certified ABECMA treatment center.
The Learn How ABECMA Is Made video can help your patients understand the ABECMA manufacturing process
The Meet your ABECMA Care Team video can help educate your patients on the trained professionals they may encounter
See a summary of select steps of the ABECMA treatment process below.
Manufacturing success rate in the pivotal study1‡
Target turnaround time for commercial manufacturing (for >90% of batches)3§
Treatment center staff will work together to manage and treat any symptoms that may arise.
Patients should be instructed to stay within 2 hours of the certified healthcare facility for at least 4 weeks after infusion.
The manufacturing success rate is defined as the ability to manufacture the product. The risk of manufacturing failure was 1.5% (2/135) in the pivotal study.
Manufacturing turnaround times may vary. The median time from leukapheresis to product availability was 33 days (range: 26 to 49 days) in the KarMMa study.
CAR=chimeric antigen receptor; CRS=cytokine release syndrome; IV=intravenous; LN2=liquid nitrogen; MM=multiple myeloma; NT=neurologic toxicity; PI=proteasome inhibitor; REMS=Risk Evaluation and Mitigation Strategy.